Related Experiment Video
Updated: Jun 17, 2025
Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model
Published on: April 13, 2015
Probing the killing potency of tumor-infiltrating lymphocytes on microarrayed colorectal cancer tumoroids
Devanjali Dutta1,2, L Francisco Lorenzo-Martín1, François Rivest1,3
1Laboratory of Stem Cell Bioengineering, Institute of Bioengineering, School of Life Sciences and School of Engineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
Abstract:
Immunotherapy has emerged as a new standard of care for certain cancer patients with specific cellular and molecular makeups. However, there is still an unmet need for ex vivo models able to readily assess the effectiveness of immunotherapeutic treatments in a high-throughput and patient-specific manner. To address this issue, we have developed a microarrayed system of patient-derived tumoroids with recreated immune microenvironments that are optimized for the high-content evaluation of tumor-infiltrating lymphocyte functionality. Here we show that this system offers unprecedented opportunities to evaluate tumor immunogenicity, characterize the response to immunomodulators, and explore novel approaches for personalized immuno-oncology.
Insights
Researchers developed a novel microarrayed system using patient-derived tumoroids and recreated immune microenvironments. This high-throughput platform enables personalized assessment of immunotherapies and tumor-infiltrating lymphocyte functionality for improved cancer treatment strategies.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Immunotherapy is a standard cancer treatment for select patients.
- Current ex vivo models lack the capacity for high-throughput, patient-specific assessment of immunotherapeutic efficacy.
- There is a need for advanced models to evaluate immune responses in the tumor microenvironment.
Purpose of the Study:
- To develop and validate a novel microarrayed system for evaluating patient-specific immunotherapies.
- To enable high-content analysis of tumor-infiltrating lymphocyte functionality within a recreated immune microenvironment.
- To facilitate personalized immuno-oncology research and drug development.
Main Methods:
- Development of a microarrayed system integrating patient-derived tumoroids.
- Recreation of tumor microenvironments within the microarray system.
- High-content evaluation of tumor-infiltrating lymphocyte functionality and response to immunomodulators.
Main Results:
- The developed system allows for high-throughput, patient-specific assessment of immunotherapeutic effectiveness.
- Demonstrated unprecedented opportunities to evaluate tumor immunogenicity.
- Enabled characterization of responses to immunomodulators and exploration of novel personalized immuno-oncology approaches.
Conclusions:
- The novel microarrayed tumoroid system addresses the unmet need for effective ex vivo assessment of immunotherapies.
- This platform provides a powerful tool for personalized medicine in immuno-oncology.
- Facilitates advancements in understanding tumor immunology and developing targeted cancer treatments.
